Human Protein Atlas

CZI Launches AI Advisory Group and Residency Program to Accelerate Development of Virtual Cell Models

Retrieved on: 
Thursday, March 21, 2024
Research, Health, McGill University, Faculty, Organization, OpenAI, Human Protein Atlas, Computer science, CZI, Associate, Disease, Meta, AI, Chan Zuckerberg Initiative, Biology, Harvard University, Former, Nature, Partner, Stanford University, Biological engineering, Artificial intelligence, Medical device

REDWOOD CITY, Calif., March 21, 2024 /PRNewswire/ -- Today, the Chan Zuckerberg Initiative (CZI) announced several key appointments and a new AI residency program to advance the organization's AI strategy for science, which is focused on building predictive models of healthy and diseased cells. Several AI experts from academia and industry have joined a newly established AI Advisory Group, which will provide guidance to leaders at CZI and across the Chan Zuckerberg Biohub Network as these organizations work to enable AI at scale for nonprofit life science research. In addition, CZI is launching an AI residency program to develop foundational AI/ML models and tools that will enable new scientific breakthroughs. Theofanis Karaletsos, a technology leader in AI/ML research and science, has also been hired as CZI's Head of Artificial Intelligence for Science.

Key Points: 
  • In addition, CZI is launching an AI residency program to develop foundational AI/ML models and tools that will enable new scientific breakthroughs.
  • These advisors have deep expertise in leveraging AI/ML models and methods to advance scientific research:
    Sam Altman, CEO of OpenAI.
  • Karaletsos will lead CZI's AI strategy for science, including the organization's vision to develop virtual cell models, utilizing one of the largest high-performance AI computing system s for nonprofit life science research.
  • He will collaborate with scientific leaders at CZI including Emma Lundberg, a member of CZI's AI Advisory Group and an Associate Professor of Bioengineering at Stanford University, to launch an in-house AI Residency Program.

Nitrase Therapeutics Presents Preclinical Data on the Role of Enzymatic Nitration in Oncology at the American Association for Cancer Research Annual Meeting

Retrieved on: 
Tuesday, April 18, 2023
AACR, Mitochondrion, Neoplasm, Overalls, Survival, Enzyme, Cancer, PAK4, Cell, RNA, Human Protein Atlas, Protein, The Cancer Genome Atlas, BAX, Annual general meeting, Escape Room, Liver, Transforming protein RhoA, Therapy, TCGA, Vaccine

“Therefore, targeted inhibition or degradation of the specific nitrase, or of the nitrated protein itself, could be a promising therapeutic approach in cancer.

Key Points: 
  • “Therefore, targeted inhibition or degradation of the specific nitrase, or of the nitrated protein itself, could be a promising therapeutic approach in cancer.
  • BAX is a specific substrate for Nitrase #11, and its cytochrome C release from the mitochondria is reduced upon nitration.
  • Utilizing The Cancer Genome Atlas (TCGA) RNA expression data and The Human Protein Atlas, nitrases were screened for association with overall survival in relation to nitrase RNA expression.
  • Additionally, several nitrases were negatively prognostic for kidney cancer or liver cancer.

Pixelgen Technologies Launches to Advance Single-Cell Spatial Proteomics

Retrieved on: 
Wednesday, December 7, 2022
Gene expression, Entrepreneurship, Human Protein Atlas, Investment, Protein, Drug discovery, Thermo Fisher Scientific, DNA, Human Cell Atlas, Biology, Genomics, Stanford University, QIAGEN, Map, Cell, Marketing, United States Air Force Scientific Advisory Board, Proteomics, Life Technologies, Microscope, Management, Fredriksson

STOCKHOLM, Dec. 7, 2022 /PRNewswire/ -- Pixelgen Technologies emerged from stealth today with a mission to bring a new dimension to single-cell spatial proteomics. The launch follows the close of an approximate $6 million seed round, led by Navigare Ventures, which will support the commercialization next year of the company's groundbreaking Molecular Pixelation technology for spatial analyses of cell surface proteins in 3D.

Key Points: 
  • STOCKHOLM, Dec. 7, 2022 /PRNewswire/ -- Pixelgen Technologies emerged from stealth today with a mission to bring a new dimension to single-cell spatial proteomics.
  • Yet, cell function and activity are primarily governed by the spatial orchestration of cell surface proteins, particularly immune cells.
  • Understanding cellular activity through the spatial organization of proteins remains largely uncharted because current tools cannot identify many proteins simultaneously and map their spatial inter-relationships.
  • Molecular Pixelation is the only technology able to show spatial protein polarization and co-localization on the cell surface in a highly multiplexed manner.

BioAegis Therapeutics to Present “Conquering Pneumonia and Systemic Inflammation with a Human Protein,” at the MACRO Trends Investor Conference in Belgium

Retrieved on: 
Friday, October 29, 2021
Death, Infection, Kidney, Lists of diseases, Disease, IP, Inflammation, Patient, Degenerative disease, Manifest and latent functions and dysfunctions, Multiple sclerosis, Telephone numbers in South Africa, Risk, ICU, Conference, MACRO, End organ damage, Steroid, COVID-19, Investor relations, COO, Gold, King Juan Carlos University, Survivor, Therapy, Mortality, Human Protein Atlas, GLOBE, Gelsolin (cellular), Pharmaceutical industry, Vaccine

Co-founders Valerie Ceva, COO, and Steven Cordovano, Vice President of Investor Relations, will present Conquering Pneumonia and Systemic Inflammation with a Human Protein, and highlight gelsolin, BioAegis novel host-directed treatment.

Key Points: 
  • Co-founders Valerie Ceva, COO, and Steven Cordovano, Vice President of Investor Relations, will present Conquering Pneumonia and Systemic Inflammation with a Human Protein, and highlight gelsolin, BioAegis novel host-directed treatment.
  • Supplementing human gelsolin with a recombinant form is a host-directed approach to treating inflammatory and infectious diseases.
  • Gelsolin, a naturally occurring human protein that is abundant in healthy individuals, is a key component of the bodys innate immune system.
  • BioAegis will also have US biologics exclusivity and has recently filed new IP in areas of unmet need.

T-Cure Bioscience, Inc. and Atlas Antibodies AB Enter a Collaboration Agreement for the Development, Manufacture, and Supply of CT83 (KK-LC-1) Monoclonal Antibodies

Retrieved on: 
Tuesday, October 5, 2021
Oncology, Health, Other Science, Clinical Trials, Science, Pharmaceutical, Biotechnology, Human Protein Atlas, Clinical trial, Neoplasm, Biomedical Research, Patient, Therapy, Cancer, Pathology, KTH, Atlas, Vii, Kidney cancer, Lung cancer, Marketing, Company, Antibody, Stomach, Mab, Growth, Royal institute, IHC, TCR, Antigen, Uppsala University, Research, Forward-looking statement, Business, Lung, Vaccine

Patients with KK-LC-1 positive tumors may be eligible for inclusion in clinical trials of a KK-LC-1 targeted T-Cell therapy.

Key Points: 
  • Patients with KK-LC-1 positive tumors may be eligible for inclusion in clinical trials of a KK-LC-1 targeted T-Cell therapy.
  • Under the terms of the agreement, Atlas Antibodies AB will provide all manufacturing and product supply for KK-LC-1 mAb for the companion diagnostic for clinical development.
  • T-Cure plans to develop the companion diagnostic assay to identify KK-LC-1 positive cancer patients for inclusion in the company sponsored clinical trial planned for 2022.
  • Headquartered in Stockholm, Sweden, Atlas Antibodies provides high-quality reagents for biomedical research, including polyclonal and monoclonal antibodies and QPrESTs.

Akoya to Help Support the Human Cell Atlas (HCA) Initiative with Single-Cell, Spatial Imaging Capabilities

Retrieved on: 
Tuesday, March 23, 2021
Oncology, Health, Genetics, Research, Science, Pharmaceutical, Biotechnology, Biological databases, Online databases, Proteomics, Human Cell Atlas, Akoya, Human Protein Atlas

Akoya Biosciences, Inc., The Spatial Biology Company, today announced its support for the Human Cell Atlas (HCA) initiative, offering the CODEX solutions single-cell, whole-tissue imaging capabilities to HCA members under favorable commercial terms.

Key Points: 
  • Akoya Biosciences, Inc., The Spatial Biology Company, today announced its support for the Human Cell Atlas (HCA) initiative, offering the CODEX solutions single-cell, whole-tissue imaging capabilities to HCA members under favorable commercial terms.
  • The mission of the Human Cell Atlas is to create comprehensive reference maps of all human cells to describe and define the cellular basis of health and disease.
  • Spatial phenotyping is a critical next step in single-cell biology which can be used to build a comprehensive cell atlas of human tissues.
  • The value of the CODEX platform is to provide unbiased, whole tissue and single-cell imaging, which could greatly contribute towards building a cell atlas and advancing the mission of the Human Cell Atlas initiative, said Brian McKelligon, CEO of Akoya.

Horizon Discovery Partners With the Human Protein Atlas

Retrieved on: 
Tuesday, December 3, 2019
Health, Physical therapy, Research, Pharmaceutical, Science, Biotechnology, Branches of biology, Biology, Life sciences, Biotechnology, Horizon Discovery, Molecular biology, Emerging technologies, Non-coding RNA, Human Protein Atlas, CRISPR

Horizon Discovery Group plc (LSE: HZD) (Horizon), a global leader in the application of gene editing and gene modulation for cell line engineering, today announced that it has entered into a partnership with The Human Protein Atlas (HPA).

Key Points: 
  • Horizon Discovery Group plc (LSE: HZD) (Horizon), a global leader in the application of gene editing and gene modulation for cell line engineering, today announced that it has entered into a partnership with The Human Protein Atlas (HPA).
  • The Horizon cell models will be integrated specifically within the HPA Cell Atlas program, which details the subcellular localization of proteins in single human cells, providing high-resolution insights into molecular mechanisms.
  • Professor Emma Lundberg, responsible for the HPA Cell Atlas program, explained: Horizon has over a decade of experience in gene editing, and a well-established reputation for providing CRISPR-edited knockout cell models.
  • Terry Pizzie, CEO, Horizon Discovery, said: Having contributed to several thousands of publications in the field of human biology and disease, the HPA is a highly regarded knowledge provider and an expert in the field of molecular mechanisms of the human cell.